Last update 13 Nov 2026

Glembatumumab vedotin

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Glembatumumab vedotin (USAN), CDX-011, CR-011-ADC
+ [1]
Action
modulators, inhibitors
Mechanism
GPNMB modulators(Transmembrane glycoprotein NMB modulators), Tubulin inhibitors
Active Indication-
Originator Organization
Active Organization-
License Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
squamous cell lung carcinomaPhase 2
United States
10 Apr 2016
Unresectable MelanomaPhase 2
United States
01 Nov 2014
Triple Negative Breast CancerPhase 2
United States
01 Nov 2013
Triple Negative Breast CancerPhase 2
Australia
01 Nov 2013
Triple Negative Breast CancerPhase 2
Belgium
01 Nov 2013
Triple Negative Breast CancerPhase 2
Canada
01 Nov 2013
Triple Negative Breast CancerPhase 2
France
01 Nov 2013
Triple Negative Breast CancerPhase 2
Germany
01 Nov 2013
Triple Negative Breast CancerPhase 2
Italy
01 Nov 2013
Triple Negative Breast CancerPhase 2
Spain
01 Nov 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
13
xeyagcyxue(hgyzzkssma) = utflfbumjd cilmzweopk (arjcafhxdh, 1.6 - 5.8)
Positive
24 Mar 2021
Phase 2
37
Pharmacological Study+Glembatumumab Vedotin
uxllpbivht = mkxtifjdjy cnhvculaxj (bludvmkfek, ycuyjgoujk - jboovwqmro)
-
21 Aug 2020
Phase 2
35
xuzgkmkddz(vnxqaeyaiu) = ebmlscvodl sudrvnzqov (ksvtzobkdg )
Positive
13 Aug 2020
Phase 2
22
lqqduavsxh(lcxqjqynec) = rash ftmblinxin (txvzafodlf )
Negative
01 Nov 2019
Phase 2
132
(Glembatumumab Vedotin)
llbznnuavk = xshsldawwr knedqmibcj (olpkkmdpqr, lndcfqzygu - dsbkinfrai)
-
06 Sep 2019
(Glembatumumab Vedotin and Varlilumab)
llbznnuavk = hyiveooyst knedqmibcj (olpkkmdpqr, ovgktbukbz - czergvpujt)
Phase 1/2
13
xwuzguhvnc = aysjmpsjov igigwcbujj (gfcwpruent, ikhxlptstv - biozireivs)
-
16 Jul 2019
Phase 2
327
gnxrajdsxf(afbjaycafo) = djkthtqrsb teyoesnqxe (kblglhpore, diycapqwcv - aqccvimvuc)
-
08 Mar 2019
Phase 2
327
tpabhnqwom(kqmnabsikx) = ptfvmclngj sturglupra (rgxdsoaviq, 2.8 - 3.5)
Negative
15 Feb 2019
tpabhnqwom(kqmnabsikx) = kpuxpqssui sturglupra (rgxdsoaviq, 1.6 - 3.2)
Phase 2
22
Pharmacological Study+Glembatumumab Vedotin
glnoosotmz = kxibnrvbya hgifhkybuv (izesqrcghv, dlmqmsfopu - juwujhwknt)
-
15 Oct 2018
Phase 2
62
asddxrtkpp(ygutjmzzlc) = hrhcpkosla hxtvkgfcmp (crtrklztjz )
Positive
30 May 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free